Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic and
pharmacodynamic effects of intravenous DT-216 in adult patients with Friedreich Ataxia. This
single ascending dose study is randomized, double-blind, placebo-controlled.